Michael J. Tomsicek
2021 - CRISPR Therapeutics AG
In 2021, Michael J. Tomsicek earned a total compensation of $3.8M as Former Chief Financial Officer at CRISPR Therapeutics AG, a 43% increase compared to previous year.
Compensation breakdown
| Option Awards | $2,108,763 |
|---|---|
| Salary | $435,483 |
| Stock Awards | $1,204,920 |
| Other | $11,600 |
| Total | $3,760,766 |
Tomsicek received $2.1M in option awards, accounting for 56% of the total pay in 2021.
Tomsicek also received $435.5K in salary, $1.2M in stock awards and $11.6K in other compensation.
Rankings
In 2021, Michael J. Tomsicek's compensation ranked 3,549th out of 12,412 executives tracked by ExecPay. In other words, Tomsicek earned more than 71.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,549 out of 12,412 | 71st |
Division Manufacturing | 1,455 out of 5,498 | 74th |
Major group Chemicals And Allied Products | 589 out of 2,374 | 75th |
Industry group Drugs | 526 out of 2,095 | 75th |
Industry Biological Products, Except Diagnostic Substances | 138 out of 452 | 70th |
Source: SEC filing on April 25, 2022.
Tomsicek's colleagues
We found five more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2021.
2021
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
2021
Brendan Smith
CRISPR Therapeutics AG
Chief Financial Officer
2021
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
2021
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
2021
James Kasinger
CRISPR Therapeutics AG
General Counsel
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019
ABIOMED CEO Michael Minogue's 2018 pay slips 16% to $10M
June 22, 2018